Literature DB >> 10606625

Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection.

J Trambley1, A W Bingaman, A Lin, E T Elwood, S Y Waitze, J Ha, M M Durham, M Corbascio, S R Cowan, T C Pearson, C P Larsen.   

Abstract

Simultaneous blockade of the CD40 and CD28 costimulatory pathways is an effective treatment strategy to promote allograft acceptance but does not lead to indefinite allograft survival. The immune mechanisms responsible for costimulation-independent rejection are not defined. Here we have studied the rejection responses of murine C57BL/6 recipients, which we show to be relatively resistant to inhibition by combined CD40/CD28 blockade. We demonstrate that asialo GM1(+) CD8(+) cells play a critical role in this costimulation blockade-resistant rejection. These results provide new insights into the costimulatory requirements for T-cell subsets and demonstrate for the first time that combined blockade of the CD40 and CD28 pathways does not adequately inhibit CD8-mediated skin allograft rejection. Furthermore, we provide evidence that asialo GM1 is a potentially important therapeutic target for CD8-dependent immune responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10606625      PMCID: PMC409885          DOI: 10.1172/JCI8082

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.

Authors:  A D Kirk; D M Harlan; N N Armstrong; T A Davis; Y Dong; G S Gray; X Hong; D Thomas; J H Fechner; S J Knechtle
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

2.  Allogeneic heart transplantation activates alloreactive NK cells.

Authors:  E Petersson; O Ostraat; H Ekberg; J Hansson; M Simanaitis; T Brodin; M Dohlsten; G Hedlund
Journal:  Cell Immunol       Date:  1997-01-10       Impact factor: 4.868

3.  Skin graft tolerance across a discordant xenogeneic barrier.

Authors:  Y Zhao; K Swenson; J J Sergio; J S Arn; D H Sachs; M Sykes
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

4.  Costimulation of CD28- T lymphocytes by 4-1BB ligand.

Authors:  M A DeBenedette; A Shahinian; T W Mak; T H Watts
Journal:  J Immunol       Date:  1997-01-15       Impact factor: 5.422

5.  CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection.

Authors:  J K Whitmire; M K Slifka; I S Grewal; R A Flavell; R Ahmed
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

6.  CD4+ but not CD8+ cells are essential for allorejection.

Authors:  N R Krieger; D P Yin; C G Fathman
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

7.  Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.

Authors:  G S Early; W Zhao; C M Burns
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

8.  Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis.

Authors:  I S Grewal; H G Foellmer; K D Grewal; J Xu; F Hardardottir; J L Baron; C A Janeway; R A Flavell
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

9.  4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.

Authors:  W W Shuford; K Klussman; D D Tritchler; D T Loo; J Chalupny; A W Siadak; T J Brown; J Emswiler; H Raecho; C P Larsen; T C Pearson; J A Ledbetter; A Aruffo; R S Mittler
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

10.  Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells.

Authors:  C Kurts; H Kosaka; F R Carbone; J F Miller; W R Heath
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

View more
  111 in total

1.  Skin allograft maintenance in a new synchimeric model system of tolerance.

Authors:  N N Iwakoshi; T G Markees; N Turgeon; T Thornley; A Cuthbert; J Leif; N E Phillips; J P Mordes; D L Greiner; A A Rossini
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

2.  A rendezvous before rejection: where do T cells meet transplant antigens?

Authors:  David M Briscoe; Mohamed H Sayegh
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

3.  Addition of an IL-15 mutant/FCgamma2A antagonist protein protects islet allografts from rejection overriding costimulation blockade.

Authors:  S Ferrari-Lacraz; X X Zheng; Y S Kim; W Maslinski; T B Strom
Journal:  Transplant Proc       Date:  2002-05       Impact factor: 1.066

4.  New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.

Authors:  Xiang Xiao; Weihua Gong; Gulcin Demirci; Wentao Liu; Silvia Spoerl; Xiufeng Chu; D Keith Bishop; Laurence A Turka; Xian C Li
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

5.  The role of natural killer T cells in costimulation blockade-based mixed chimerism.

Authors:  Patrick-Nikolaus Nierlich; Christoph Klaus; Sinda Bigenzahn; Nina Pilat; Zvonimir Koporc; Ines Pree; Ulrike Baranyi; Masaru Taniguchi; Ferdinand Muehlbacher; Thomas Wekerle
Journal:  Transpl Int       Date:  2010-11       Impact factor: 3.782

6.  Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells.

Authors:  W H Kitchens; D Haridas; M E Wagener; M Song; A D Kirk; C P Larsen; M L Ford
Journal:  Am J Transplant       Date:  2011-09-22       Impact factor: 8.086

Review 7.  Co-stimulation blockade as a new strategy in kidney transplantation: benefits and limits.

Authors:  Renaud Snanoudj; Julien Zuber; Christophe Legendre
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

8.  Recipient lymphocyte infusion in MHC-matched bone marrow chimeras induces a limited lymphohematopoietic host-versus-graft reactivity but a significant antileukemic effect mediated by CD8+ T cells and natural killer cells.

Authors:  Lien De Somer; Ben Sprangers; Sabine Fevery; Omer Rutgeerts; Caroline Lenaerts; Louis Boon; Mark Waer; An D Billiau
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

9.  Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus.

Authors:  K Singh; N Kozyr; L Stempora; A D Kirk; C P Larsen; B R Blazar; L S Kean
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

10.  CD4 and CD8 T cells require different membrane gangliosides for activation.

Authors:  Masakazu Nagafuku; Kaori Okuyama; Yuri Onimaru; Akemi Suzuki; Yuta Odagiri; Tadashi Yamashita; Katsunori Iwasaki; Michihiro Fujiwara; Motoaki Takayanagi; Isao Ohno; Jin-ichi Inokuchi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.